AstraZeneca has picked off another label expansion for its cancer blockbuster Imfinzi (durvalumab) as the FDA has ...
The US Food and Drug Administration (FDA) has granted priority review to AstraZeneca's supplemental biologics licence ...
The U.S. Food and Drug Administration has approved AstraZeneca blockbuster drug Imfinzi to treat some adults with ...
Imfinzi (durvalumab) for adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed ...
AstraZeneca's Imfinzi gains FDA Priority Review for bladder cancer. Key trial data shows improved survival and progression ...
The FDA approves AZN's Imfinzi for treating patients with limited-stage small-cell lung cancer based on phase III ADRIATIC ...
Cambridge: AstraZeneca's supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab) has been accepted and ...
AstraZeneca (AZN) said the FDA has accepted its supplemental Biologics License Application for Imfinzi for Priority Review for the treatment of muscle-invasive bladder cancer.
Imfinzi has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer, LS-SCLC ...
AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended by NICE for treating adults with ...
British drug maker AstraZeneca Plc (AZN.L, AZN) announced Thursday that the U.S. Food and Drug Administration has approved Imfinzi ...
AstraZeneca's Imfinzi (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small ...